All In Biotech

Drug Trial Radar · NCT07462650

Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer

A Phase 1/2, Biomarker-Assigned, Open-Label Dose Escalation and Expansion Study of Allogeneic Dual-Target CAR-NK Cells Targeting CEA (CEACAM5) and/or GUCY2C (GCC) With an Exploratory HER2/ERBB2-Positive Cohort in Subjects With Advanced or Metastatic Colorectal Cancer

Last checked: Nov 20, 2026Latest source record: Mar 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Feb 1, 2026

Primary completion

Dec 21, 2027

Study completion Dec 22, 2028

Sponsor

Lead sponsor
Beijing BiotechIndustry
Sponsor type
Industry
First posted
Mar 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of an allogeneic dual-target chimeric antigen receptor natural killer (CAR-NK) cell product in adults with advanced or metastatic colorectal cancer (CRC). Participants are assigned to one of three dual-target arms based on tumor antigen co-expression: (1) CEA+GUCY2C, (2) CEA+HER2, or (3) GUCY2C+HER2. Following dose escalation, the most suitable target pair (based on safety, feasibility, and early efficacy/biomarker signals) will be selected for dose expansion.

Conditions

  • Colorectal Cancer Metastatic
  • Adenocarcinoma of Colon

Interventions

  • EB-DUO-CAR-NK-CEA/GCC (IV)Biological

    Allogeneic dual-target CAR-NK cells manufactured from cord blood-derived NK cells, genetically engineered to express a tandem (dual-binding) CAR, an IL-15 support element (e.g., membrane-bound IL-15 or IL-15/IL-15R fusion), and an inducible suicide switch

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose-limiting toxicities (DLTs) graded by CTCAE v5.0.Time frame: 28 Days
  2. Maximum tolerated dose (MTD)Time frame: 28 Days
  3. Objective response rate (ORR) by RECIST v1.1 in the expansion cohort.Time frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University Shenzhen Hospital

    Shenzhen, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.